Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the American Society for Clinical Oncology’s annual meeting, June 2-6 in Chicago, Illinois, see our list of Fred Hutch research highlights at ASCO and contact [email protected] to set up interviews with experts.
Read about new melanoma treatment practices, how models provide information about a rare adrenal cancer, a potential oral medication for brain cancer, and clinical trials for cancer patients with HIV.
20210305093594.png&width=400&height=400){kind=logo}
Scientists have spent years trying to develop an effective HIV vaccine, but none have proven successful. Based on findings from a recently published study, a Johns Hopkins Medicine-led research team may have put science one step closer to that goal.
Skin cancer is the most prevalent form of cancer in the United States, with over 5 million cases diagnosed annually. The Centers for Disease Control and Prevention reports that melanoma alone accounts for more than 8,000 deaths each year. Thankfully, skin cancer is highly preventable, making it crucial to prioritize protection. Below are some of the latest headlines in the Dermatology channel.
An international study led by MELIS-UPF researchers from the Infection Biology and Molecular Virology laboratories has identified and characterized Schlafen 12 (SLFN 12) as a novel HIV restriction factor.
Rutgers Institute for Health researcher, Dr. Ashley Grosso, receives grant from NIH to conduct study on barriers to HIV research in Africa.
New research from Boston Medical Center found that people living with HIV that have had pulmonary tuberculosis had broader and more potent HIV antibody responses and differences in HIV sequences predicted to be antibody resistant as compared to those without suspected or documented tuberculosis.
Uganda’s anti-homosexuality bill, if signed into law, could lead to the withdrawal of foreign aid and threaten goals to end HIV/AIDS by 2030, advocates warn.
Patients with mpox who were treated with the antiviral drug tecovirimat had similar outcomes regardless of HIV status, find researchers at Columbia University and Weill Cornell Medicine.
Gene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells – can effectively eliminate HIV infection. The study is the first to combine a dual gene-editing strategy with antiretroviral drugs to cure animals of HIV-1.
Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.
UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CART-cell therapy.
Below are some of the latest headlines in the new Avian Flu channel on Newswise.
The National Institute of Allergy and Infectious Diseases has awarded a five-year, $15.45 million grant to the San Diego Center for AIDS Research at UC San Diego, renewing support that extends back to an original establishing grant in 1994 at the height of the AIDS epidemic.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
